Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs D Wave Quantum Inc (QBTS) Price & Performance

Abbott LaboratoriesTrade
D Wave Quantum IncTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs D Wave Quantum Inc — how do they compare? Abbott Laboratories trades at $111.21 (market cap $187.95B), while D Wave Quantum Inc trades at $20.74 (market cap $7.53B). The key difference: Abbott Laboratories is far larger — about 25× D Wave Quantum Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.

ABTQBTS
Market Cap
$187.95B$7.53B
Sector
HealthTechnology
52-Week High
$136.62$44.78
52-Week Low
$82.57$12.98
Enterprise Value
$214.96B$7.04B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

D Wave Quantum Inc

D-Wave Quantum (QBTS) trades at $20.57, up 1.86% on the day, with a bearish technical signal despite unanimous analyst buy ratings. The stock exhibits extreme valuation metrics, including a P/S ratio of 583.84, while fundamentals show deep losses with a net income margin of -2001.59% in 2026. Recent Q2 2026 earnings missed revenue estimates but highlighted a 1120% surge in bookings, per Barrons on August 6, 2026.

The outlook hinges on commercial adoption of quantum computing, offering speculative upside with a consensus price target of $38.29, but high execution risks and cash burn pose significant threats to shareholder value amid volatile sentiment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About D Wave Quantum Inc

D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.

Read more on QBTS